Eli Lilly And Co (NYSE:LLY) inked two strategic collaborations to expand radiopharmaceuticals and metabolic-associated ...

Lilly will provide an initial payment to complete a Phase I trial of OLX75016, which started in February 2024.

Eli Lilly inked two collaborations on Monday, one focused on cardiometabolic diseases with South Korea’s OliX Pharmaceuticals ...

Eli Lilly has begun the week with a bang. Early Monday morning, AdvanCell and OliX Pharmaceuticals put out news that the Big ...

Olix Pharmaceuticals Inc. walked the talk in realizing a new $630 million licensing deal with Eli Lilly and Co. for its cardiovascular and metabolic disease asset, OLX-702A (OLX-75016), rallying stock ...

Novartis, Eli Lilly and more put on their deal-making caps, Bristol Myers Squibb targets $2 billion in savings through 2027, sales continue to soar for Lilly and Novo Nordisk’s GLP-1s and Regeneron ...

OliX Pharmaceuticals, a gene therapy developer, recorded a daily limit up on the 10th after news that it signed a global ...

Recent research suggests that a new approach could help even patients with advanced forms of fatty liver disease.

South Korea-based developer of RNAi therapeutics developer OliX Pharmaceuticals has announced a global licensing agreement with Eli Lilly.

Olix Pharmaceuticals signed a $630 million licensing deal with Eli Lilly to develop treatments for cardiovascular and ...

OliX Pharmaceuticals, a developer of gene therapies, has licensed its candidate for metabolic dysfunction-associated steatotic liver disease (MASH) to the U.S. pharmaceutical company Eli Lilly. The ...

Viking Therapeutics got the market's attention with robust phase 2 results for VK2735, a potential weight loss therapy.